Skip to main content

Advertisement

Table 1 Clinical parameters of recruited subjects

From: Simultaneous identification of GSTP1 Ile105→Val105 and Ala114→Val114 substitutions using an amplification refractory mutation systempolymerase chain reactionassay: studies in patients with asthma

  FEV1 >80% predicted*  
  BHR negative BHR positive BHR positive  
  (PC20 >16 mg/ml; group 1) (PC20 8–16 mg/ml; group 2) (PC20 0.03–8 mg/ml; group3) FEV1≤80% predicted* (group 4)
Parameters     
n (%) 58 (33.9) 15 (8.8) 51 (29.8) 47 (27.5)
Mean age ± SD (years) 37.0 ± 11.9 29.3 ± 6.8 33.0 ± 11.1 41.4 ± 11.0
Males (n [%]) 18 (31.0) 4 (26.7) 13 (25.5) 16 (34.0)
Females (n [%]) 40 (69.0) 11 (73.3) 38 (74.5) 31 (66.0)
Skin test negative (n [%]) 32 (55.2) 7 (46.7) 12 (23.5) 7 (14.9)
Skin test positive (n [%]) 26 (44.8) 8 (53.3) 39 (79.5) 40 (85.1)
IgE ≤100 IU/ml* (n [%]) 38 (71.7) 10 (83.3) 21 (46.7) 16 (40.0)
IgE >100 IU/ml* (n [%]) 15 (28.3) 2 (16.9) 24 (53.3) 24 (60.0)
  1. *In some patients we were unable to obtain a complete data set. Some individuals were unwilling to undertake a metacholine challenge test, whereas others did not wish to donate a blood sample (in this case DNA was isolated from a mouthwash sample). Mean FEV1 = 67% predicted (min = 45%, max = 78%).